Biogen pulls Alzheimer’s drug application in Europe

The latest stories trending on MedCity News.

Not rendering correctly? View this email as a web page here. TOP STORIES Biogen pulls Alzheimer's drug application in Europe as EMA calls data insufficient Biogen withdrew an application seeking approval in Europe for Alzheimer's disease drug Aduhelm, a move that follows a negative opinion on the therapy issued by a European Medicines Commission committee last December. The company was unable to persuade European regulators to change their minds about the drug. SPONSORED INVEST PharmaTech From MedCity MedCity INVEST PharmaTech 2022 is a virtual executive summit where established biopharma companies gather with health tech and digital health innovators to transform the industry. Register Now Will Congressional action cement the vaunted status of telehealth beyond the pandemic? By Elizabeth Westbrook Friday, April 22, 2022 2:31 PM Providers, health systems and patient groups who want to see telehealth survive beyond the federal public health emergency need to engage their lawmakers and associations now to demonstrate the need and utility for continued telemedicine. Read more » Keep hospital operations moving while upgrading the building's systems By Mike Shea and Mike Swanson Friday, April 22, 2022 1:30 PM No one said it's easy to do construction renovation in healthcare facilities, but it is vitally important to ensure that medical facilities can deliver the best care possible. Read more » New unicorn NexHealth is growing its workforce, adding EHR features to streamline the patient experience By Michael Schroeder Friday, April 22, 2022 1:18 PM NexHealth raised $125 million in a Series C funding round that was led by Buckley Ventures, the patient experience platform announced Thursday. The latest investment brings the company's valuation to $1 billion. Read more » Biogen pulls Alzheimer's drug application in Europe as EMA calls data insufficient By Frank Vinluan Friday, April 22, 2022 12:41 PM Biogen withdrew an application seeking approval in Europe for Alzheimer's disease drug Aduhelm, a move that follows a negative opinion on the therapy issued by a European Medicines Commission committee last December. The company was unable to persuade European regulators to change their minds about the drug. Read more » SPONSORED MedCity Pivot Podcast: A conversation with Buoy Health's chief medical officer In our conversation, Adrienne McFadden, who at one time was a practicing physician, speaks about the evolution of the company to more of a curated matchmaker connecting and guiding people to the best care available. Listen Now! MedCity News   611 Broadway    New York,  NY   10012   United States You received this email because you are subscribed to MedCity Daily Digest from MedCity News. Update your email preferences to choose the types of emails you receive.  Unsubscribe from all future emails